The FDA laid out specific goals for the contractor it seeks to hire
The Food and Drug Administration (FDA) is looking to award a contract to help study CBD as the agency develops regulations for products containing the non-intoxicating cannabinoid.
In a notice published on Thursday, FDA said the chosen company will provide support with “collecting samples and assessing the quantities of CBD and related cannabinoids, as well as potential associated contaminants such as toxic elements, pesticides, industrial chemicals, processing solvents and microbial contaminants, in foods and cosmetics through surveys of these commodities.”
FDA said that the results of the studies “will not only be reported to Congress, but will also be used to guide the development of future policy” and will help to “develop a better understanding of the quantities of CBD and associated cannabinoids and their distribution.”
“The goal will be to collect and analyze a statistically relevant number of samples, between 1000-3000. The reliability of the results will be supported by specified quality assurance/quality control processes within the study. The types of samples to be collected for these studies will include food and cosmetic products from across the United States, mainly including CBD-containing packaged and processed foods such as beverages, water, candy, baked goods, oils and tinctures that can be added to human or animal foods, including pills, capsules, gel caps, gummies and other forms.”
To Read The Rest Of This Article On Marijuana Moment, Click Here